{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:11:13Z","timestamp":1790104273734,"version":"4.0.1"},"reference-count":161,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":278,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Plan Nacional I\u2009+\u2009D+I","award":["PI22\/00910 (PI E.P.)"],"award-info":[{"award-number":["PI22\/00910 (PI E.P.)"]}]},{"name":"Joan Rod\u00e9s","award":["JR24\/00046"],"award-info":[{"award-number":["JR24\/00046"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Alcohol-related liver disease (ALD) is a prevalent global health issue, contributing to significant mortality and encompassing a spectrum of liver damage from steatosis to decompensated cirrhosis and hepatocellular carcinoma. This review summarizes the current state of ALD, emphasizing both early and advanced stages, including alcohol-related hepatitis (AH). The epidemiology, diagnostic tools, natural history, and key progression factors of ALD are discussed, highlighting the role of diagnostic tools and pathways in early and advanced stages of ALD. The review also addresses the importance and particularities of the treatment of alcohol use disorder in patients with ALD, covering both psychological and pharmaceutical interventions. Finally, treatments for ALD-related fibrosis and AH are discussed, presenting both the currently available and future treatment options. The conclusions of this review underscore the need for comprehensive strategies to improve diagnosis, prognostic stratification, and treatment strategies at all stages of ALD.<\/jats:p>","DOI":"10.1093\/gastro\/goaf088","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:21:33Z","timestamp":1759756893000},"source":"Crossref","is-referenced-by-count":5,"title":["Alcohol-related liver disease"],"prefix":"10.1093","volume":"13","author":[{"given":"Queralt","family":"Herms","sequence":"first","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-7238","authenticated-orcid":false,"given":"Jordi","family":"Gratac\u00f3s-Gin\u00e8s","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic de Barcelona , Barcelona,","place":["Spain"]},{"name":"Institut d\u2019Investigacions Biome\u0300diques August Pi i Sunyer (IDIBAPS) , Barcelona,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pose","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic de Barcelona , Barcelona,","place":["Spain"]},{"name":"Institut d\u2019Investigacions Biome\u0300diques August Pi i Sunyer (IDIBAPS) , Barcelona,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2025100609212627900_goaf088-B1","volume-title":"Global Status Report on Alcohol and Health 2018","author":"World Health Organization","year":"2018"},{"key":"2025100609212627900_goaf088-B2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u2009\u2212\u20092016: a system- atic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"key":"2025100609212627900_goaf088-B4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.cgh.2022.03.017","article-title":"Alcohol-associated liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic","volume":"20","author":"Deutsch-Link","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/cld.1025","article-title":"Alcohol-related liver disease in Latin America: local solutions for a global problem","volume":"16","author":"D\u00edaz","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2025100609212627900_goaf088-B7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/alcalc\/agt004","article-title":"The economic burden of alcohol dependence in Europe","volume":"48","author":"Laramee","year":"2013","journal-title":"Alcohol Alcohol"},{"key":"2025100609212627900_goaf088-B8","author":"Health Organization Regional Office for Europe","year":"2016"},{"key":"2025100609212627900_goaf088-B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0014-7","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025100609212627900_goaf088-B10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1365-2036.2007.03302.x","article-title":"Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features","volume":"25","author":"Mathurin","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100609212627900_goaf088-B11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis","volume":"57","author":"Garc\u00eda-Pag\u00e1n","year":"2012","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroent Gastroenterol"},{"key":"2025100609212627900_goaf088-B14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0140-6736(81)91984-X","article-title":"Alcoholic liver disease: morphological manifestations. Review by an international group","volume":"1","author":"An International Group","year":"1981","journal-title":"Lancet"},{"key":"2025100609212627900_goaf088-B15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","article-title":"Alcoholic liver disease: pathogenesis and new therapeutic tar- gets","volume":"141","author":"Gao","year":"2011","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2018.02.022","article-title":"The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis","volume":"69","author":"Serst\u00e9","year":"2018","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep4.1874","article-title":"Severe alcohol-associated hepatitis is associated with worse survival in critically ill patients with acute on chronic liver failure","volume":"6","author":"Patidar","year":"2022","journal-title":"Hepatol Commun"},{"key":"2025100609212627900_goaf088-B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/hep.510250120","article-title":"Excess weight risk factor for alcoholic liver disease","volume":"25","author":"Naveau","year":"1997","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B19","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and meta- analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025100609212627900_goaf088-B20","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1111\/liv.15692","article-title":"Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers","volume":"43","author":"Stankevic","year":"2023","journal-title":"Liver Int"},{"key":"2025100609212627900_goaf088-B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng.488","article-title":"Variant in PNPLA3 is associated with alcoholic liver disease","volume":"42","author":"Tian","year":"2010","journal-title":"Nat Genet"},{"key":"2025100609212627900_goaf088-B22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome- wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"2025100609212627900_goaf088-B23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein- truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100609212627900_goaf088-B24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1053\/j.gastro.2020.06.014","article-title":"Genome- wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1","volume":"159","author":"Innes","year":"2020","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.510230513","article-title":"Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study","volume":"23","author":"Becker","year":"1996","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/apt.16461","article-title":"Alcohol- associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics","volume":"54","author":"Singal","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100609212627900_goaf088-B27","doi-asserted-by":"crossref","first-page":"e0490","DOI":"10.1097\/HC9.0000000000000490","article-title":"Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality","volume":"8","author":"Alvarado-Tapias","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025100609212627900_goaf088-B28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B29","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/liv.14830","article-title":"Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study","volume":"41","author":"Pose","year":"2021","journal-title":"Liver Int"},{"key":"2025100609212627900_goaf088-B30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers","volume":"76","author":"Whitfield","year":"2022","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B31","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B32","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"key":"2025100609212627900_goaf088-B33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bpg.2017.09.003","article-title":"Alcohol, smoking and the liver disease patient","volume":"31","author":"Hagstr\u00f6m","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025100609212627900_goaf088-B34","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/j.1572-0241.2008.01948.x","article-title":"Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study","volume":"103","author":"Bedogni","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2025100609212627900_goaf088-B35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0741-8329(03)00128-9","article-title":"Hemochromatosis and alcoholic liver disease","volume":"30","author":"Fletcher","year":"2003","journal-title":"Alcohol"},{"key":"2025100609212627900_goaf088-B36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/apt.13523","article-title":"Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis","volume":"43","author":"Kennedy","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100609212627900_goaf088-B37","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide","volume":"17","author":"Shah","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2025100609212627900_goaf088-B38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2018.11.025","article-title":"Non-Invasive Diagnosis and Biomarkers in Alcohol-Related Liver Disease","volume":"70","author":"Moreno","year":"2019","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/HEP.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B41","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/J.JHEP.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/J.JHEP.2021.05.025","article-title":"Liver. EASL Clinical Practice Guidelines on non- invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B44","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, vali- dation, and prognostic evaluation of a risk score for long-term liver- related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"key":"2025100609212627900_goaf088-B45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B47","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S2468-1253(18)30124-9","article-title":"Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis","volume":"3","author":"Nguyen-Khac","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B48","doi-asserted-by":"publisher","first-page":"101165","DOI":"10.1016\/J.JHEPR.2024.101165","article-title":"Liver fibrosis screening increases alcohol abstinence","volume":"6","author":"Avitabile","year":"2024","journal-title":"JHEP Rep"},{"key":"2025100609212627900_goaf088-B49","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B50","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000231","article-title":"Suboptimal diagnostic accuracy of ultrasound and CT for compensated cirrhosis: evidence from prospective cohort studies","volume":"7","author":"Hetland","year":"2023","journal-title":"Hepatol Commun"},{"key":"2025100609212627900_goaf088-B51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/a-2541-2892","article-title":"Diagnosis and management of early stages of ALD","volume":"45","author":"Gratac\u00f3s-Gin\u00e8s","year":"2025","journal-title":"Semin Liver Dis"},{"key":"2025100609212627900_goaf088-B52","doi-asserted-by":"publisher","first-page":"CD010542","DOI":"10.1002\/14651858.C","article-title":"Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease","volume":"1","author":"Pavlov","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100609212627900_goaf088-B53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jhep.2022.03.024","article-title":"Corrigendum to 'Baveno VII\u2014Renewing consensus in portal hypertension\u2019 [J Hepatol (2022) 959-974]","volume":"77","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B55","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100609212627900_goaf088-B56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3109\/00365528309181659","article-title":"The accuracy of the clinical diagnosis in acute hepatitis and alcoholic liver disease. Clinical versus morphological diagnosis","volume":"18","author":"Kryger","year":"1983","journal-title":"Scand J Gastroenterol"},{"key":"2025100609212627900_goaf088-B57","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hep.29080","article-title":"A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis","volume":"66","author":"Bissonnette","year":"2017","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B58","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.cgh.2023.03.023","article-title":"Adding inflammatory markers and refining national institute on alcohol abuse and alcoholism criteria improve diagnostic accuracy for alcohol-associated hepatitis","volume":"21","author":"Avitabile","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2025100609212627900_goaf088-B61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41572-022-00406-1","article-title":"Hazardous drinking and alcohol use disorders","volume":"8","author":"MacKillop","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2025100609212627900_goaf088-B62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41575-021-00527-0","article-title":"Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation","volume":"19","author":"Arab","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B63","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"2025100609212627900_goaf088-B64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/alcalc\/agad051","article-title":"Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials","volume":"58","author":"Hemrage","year":"2023","journal-title":"Alcohol Alcohol"},{"key":"2025100609212627900_goaf088-B65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/alcalc\/agt170","article-title":"The impact of brief alcohol interventions in primary healthcare: a systematic review of reviews","volume":"49","author":"O'Donnell","year":"2014","journal-title":"Alcohol Alcohol"},{"key":"2025100609212627900_goaf088-B66","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.cgh.2022.08.001","article-title":"Psychotherapy for alcohol use disorder is associated with reduced risk of incident alcohol-associated liver disease","volume":"21","author":"Vannier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B67","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/ADM.0000000000000315","article-title":"Patients\u2019 knowledge and attitudes towards regular alcohol urine screening: a survey study","volume":"11","author":"Barrio","year":"2017","journal-title":"J Addict Med"},{"key":"2025100609212627900_goaf088-B68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.drugalcdep.2017.11.015","article-title":"Filling the gap between lab and clinical impact: an open randomized diagnostic trial comparing urinary ethylglucuronide and ethanol in alcohol dependent outpatients","volume":"183","author":"Barrio","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025100609212627900_goaf088-B69","doi-asserted-by":"publisher","first-page":"356","DOI":"10.15288\/JSA.1990.51.356","article-title":"Failure of a 2-hour motivational intervention to alter recurrent drinking behavior in alcoholics with gastrointestinal disease","volume":"51","author":"Kuchipudi","year":"1990","journal-title":"J Stud Alcohol"},{"key":"2025100609212627900_goaf088-B70","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/LT.22259","article-title":"A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation","volume":"17","author":"Weinrieb","year":"2011","journal-title":"Liver Transpl"},{"key":"2025100609212627900_goaf088-B71","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10461-020-03062-2","article-title":"A randomized trial comparing brief advice and motivational interviewing for persons with HIV-HCV co-infection who drink alcohol","volume":"25","author":"Stein","year":"2021","journal-title":"AIDS Behav"},{"key":"2025100609212627900_goaf088-B72","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/hep.31058","article-title":"A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection","volume":"71","author":"Proeschold-Bell","year":"2020","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B73","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/add.12679","article-title":"Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial","volume":"109","author":"Dieperink","year":"2014","journal-title":"Addiction"},{"key":"2025100609212627900_goaf088-B74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cgh.2015.07.047","article-title":"Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review","volume":"14","author":"Khan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B75","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/hep.30358","article-title":"Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease","volume":"70","author":"Caputo","year":"2019","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B76","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1053\/jlts.2003.50152","article-title":"First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation","volume":"9","author":"Georgiou","year":"2003","journal-title":"Liver Transpl"},{"key":"2025100609212627900_goaf088-B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108396","article-title":"Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic","volume":"130","author":"Mellinger","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2025100609212627900_goaf088-B78","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1001\/archinte.159.16.1946","article-title":"A randomized trial of integrated outpatient treatment for medically ill alcoholic men","volume":"159","author":"Willenbring","year":"1999","journal-title":"Arch Intern Med"},{"key":"2025100609212627900_goaf088-B79","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/acer.12117","article-title":"Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center","volume":"37","author":"Addolorato","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"2025100609212627900_goaf088-B80","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0168-8278(94)80249-1","article-title":"Disulfiram-induced hepatitis. Report of four cases and review of the literature","volume":"21","author":"Forns","year":"1994","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bmj.2.6079.94","article-title":"Disulfiram hepatotoxicity","volume":"2","author":"Ranek","year":"1977","journal-title":"Br Med J"},{"key":"2025100609212627900_goaf088-B82","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol Commun"},{"key":"2025100609212627900_goaf088-B83","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(23)00447-6","article-title":"Naltrexone is safe and effective in achieving abstinence and reducing alcohol craving in cirrhotic patients: a double blind randomized placebo controlled trial","volume":"78","author":"Alla","year":"2023","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice","volume":"34","author":"Tyson","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B85","doi-asserted-by":"publisher","first-page":"e0093","DOI":"10.1097\/HC9.0000000000000093","article-title":"Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis","volume":"7","author":"Rabiee","year":"2023","journal-title":"Hepatol Commun"},{"key":"2025100609212627900_goaf088-B86","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"2025100609212627900_goaf088-B87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2025100609212627900_goaf088-B88","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"2025100609212627900_goaf088-B89","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2025100609212627900_goaf088-B90","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B91","doi-asserted-by":"crossref","first-page":"E2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025100609212627900_goaf088-B92","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2020.12.004","article-title":"Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis","volume":"74","author":"Avance\u00f1a","year":"2021","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12876-023-02656-z","article-title":"Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis","volume":"23","author":"Alexandre","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2025100609212627900_goaf088-B94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcp.12182","article-title":"CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores","volume":"77","author":"Albarmawi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025100609212627900_goaf088-B95","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.cgh.2020.10.026","article-title":"Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group","volume":"19","author":"Im","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jsat.2018.05.003","article-title":"Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis","volume":"91","author":"Mellinger","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2025100609212627900_goaf088-B97","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.dld.2024.01.195","article-title":"You can\u2019t handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients","volume":"56","author":"Scholten","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2025100609212627900_goaf088-B98","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","article-title":"Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis","volume":"22","author":"Nasr","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B99","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease [published correction appears in J Hepatol. 2023 May; 78(5):1080-1083. doi: 10.1016\/j.jhep.2023.01.018.]","volume":"78","author":"Staufer","year":"2023","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B100","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s11695-023-06490-w","article-title":"B. ariatric surgery is associated with alcohol- related liver disease and psychiatric disorders associated with AUD","volume":"33","author":"Alvarado-Tapias","year":"2023","journal-title":"Obes Surg"},{"key":"2025100609212627900_goaf088-B101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"2025100609212627900_goaf088-B102","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000561","article-title":"Transforming steatotic liver disease management: the emerging role of GLP-1 receptor agonists","volume":"8","author":"Jensen","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025100609212627900_goaf088-B103","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2011.134","article-title":"Alcoholic liver disease: pathogenesis and new targets for therapy","volume":"8","author":"Altamirano","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B104","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S","article-title":"Rifaximin-\u03b1 for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo- controlled, phase 2 trial","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B105","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B106","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/J.CGH.2023.04.017","article-title":"Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease","volume":"22","author":"Sharma","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B107","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case- cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100609212627900_goaf088-B108","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"2025100609212627900_goaf088-B109","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMOA2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100609212627900_goaf088-B110","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/J.CGH.2023.06.004","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B111","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/J.CGH.2021.07.010","article-title":"Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes","volume":"20","author":"Simon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B112","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1038\/S41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"2025100609212627900_goaf088-B113","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/JAMAPSYCHIATRY.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2025100609212627900_goaf088-B114","doi-asserted-by":"publisher","first-page":"156057","DOI":"10.1016\/J.METABOL.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"2025100609212627900_goaf088-B115","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/J.CMET.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"2025100609212627900_goaf088-B116","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B117","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMOA2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100609212627900_goaf088-B118","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/J.CMET.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab"},{"key":"2025100609212627900_goaf088-B119","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/HEP.20399","article-title":"Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage","volume":"40","author":"Nakajima","year":"2004","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/J.BBRC.2022.04.132","article-title":"PPAR\u03b1 agonist WY-14,643 induces the PLA2\/COX- 2\/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice","volume":"613","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"2025100609212627900_goaf088-B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.TRSL.2020.06.006","article-title":"The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice","volume":"227","author":"Chu","year":"2021","journal-title":"Transl Res"},{"key":"2025100609212627900_goaf088-B122","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.3748\/WJG.V30.I28.3428","article-title":"Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease","volume":"30","author":"Koizumi","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2025100609212627900_goaf088-B123","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100609212627900_goaf088-B124","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B125","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2021.06.019","article-title":"Identification of optimal therapeutic window for steroid use in severe alcohol- associated hepatitis: a worldwide study","volume":"75","author":"Arab","year":"2021","journal-title":"J Hepatol"},{"key":"2025100609212627900_goaf088-B126","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"key":"2025100609212627900_goaf088-B127","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B128","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2468-1253(21)00430-","article-title":"Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study","volume":"7","author":"Louvet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100609212627900_goaf088-B129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ajt.13586","article-title":"Early liver transplantation for severe alcoholic hepatitis in the United States\u2014a single- center experience","volume":"16","author":"Im","year":"2016","journal-title":"Am J Transplant"},{"key":"2025100609212627900_goaf088-B130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0000000000001831","article-title":"Three-year results of a pilot program in early liver transplantation for severe alcoholic hepatitis","volume":"265","author":"Lee","year":"2017","journal-title":"Ann Surg"},{"key":"2025100609212627900_goaf088-B131","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis","volume":"155","author":"Lee","year":"2018","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B132","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/hep.30478","article-title":"Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post\u2013liver transplant score","volume":"69","author":"Lee","year":"2019","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B133","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin Nutr"},{"key":"2025100609212627900_goaf088-B134","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B135","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"2025100609212627900_goaf088-B136","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol- associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B137","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.matbio.2017.09.003","article-title":"The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis","volume":"66","author":"Kim","year":"2018","journal-title":"Matrix Biol"},{"key":"2025100609212627900_goaf088-B138","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hep.29144","article-title":"MicroRNA 181b-3p and its target importin \u03b15 regulate toll-like receptor 4 signaling in Kupffer cells and liver injury in mice in response to ethanol","volume":"66","author":"Saikia","year":"2017","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B139","doi-asserted-by":"publisher","first-page":"107","DOI":"10.14309\/ajg.0000000000002275","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis","volume":"119","author":"Hassanein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2025100609212627900_goaf088-B140","first-page":"2101","article-title":"TAK242 suppresses the TLR4 signaling pathway and ameliorates DCD liver IRI in rats","volume":"20","author":"Zhong","year":"2019","journal-title":"Mol Med Rep"},{"key":"2025100609212627900_goaf088-B141","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cmet.2018.01.007","article-title":"Digoxin suppresses pyruvate kinase M2-promoted HIF-1\u03b1 transactivation in steatohepatitis","volume":"27","author":"Ouyang","year":"2018","journal-title":"Cell Metab"},{"key":"2025100609212627900_goaf088-B142","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B143","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/HMER.S230613","article-title":"Evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: a brief report on emerging data","volume":"12","author":"Diaz Soto","year":"2020","journal-title":"Hepat Med"},{"key":"2025100609212627900_goaf088-B144","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1665-2681(19)30863-4","article-title":"Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis","volume":"13","author":"Higuera-de la Tijera","year":"2014","journal-title":"Ann Hepatol"},{"key":"2025100609212627900_goaf088-B145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cells12010022","article-title":"Current therapeutic options and potential of mesenchymal stem cell therapy for alcoholic liver disease","volume":"12","author":"Han","year":"2022","journal-title":"Cells"},{"key":"2025100609212627900_goaf088-B146","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12964-023-01230-0","article-title":"A new perspective on mesenchymal stem cell-based therapy for liver diseases: restoring mitochondrial function","volume":"21","author":"Cen","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2025100609212627900_goaf088-B147","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/stcltm\/szad082","article-title":"Recent advances in mesenchymal stem\/stromal cell-based therapy for alcohol-associated liver disease and non-alcoholic fatty liver disease","volume":"13","author":"Korkida","year":"2024","journal-title":"Stem Cells Transl Med"},{"key":"2025100609212627900_goaf088-B148","doi-asserted-by":"crossref","first-page":"1215333","DOI":"10.3389\/fimmu.2023.1215333","article-title":"NLRP3: a new therapeutic target in alcoholic liver disease","volume":"14","author":"Brahadeeswaran","year":"2023","journal-title":"Front Immunol"},{"key":"2025100609212627900_goaf088-B149","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/978-3-031-32483-3_60","volume-title":"Alcohol and Alcohol-Related Diseases","author":"Perez","year":"2023"},{"key":"2025100609212627900_goaf088-B150","doi-asserted-by":"crossref","first-page":"101689","DOI":"10.1016\/j.eclinm.2022.101689","article-title":"A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis","volume":"54","author":"Tayek","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025100609212627900_goaf088-B151","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.jhepr.2020.100139","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"key":"2025100609212627900_goaf088-B152","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B153","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B154","doi-asserted-by":"crossref","first-page":"e00306","DOI":"10.14309\/ctg.0000000000000306","article-title":"No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation","volume":"12","author":"St\u00f8y","year":"2021","journal-title":"Clin Transl Gastroenterol."},{"key":"2025100609212627900_goaf088-B155","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial","volume":"329","author":"Louvet","year":"2023","journal-title":"JAMA"},{"key":"2025100609212627900_goaf088-B156","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH)","volume":"42","author":"Jim\u00e9nez","year":"2022","journal-title":"Liver Int"},{"key":"2025100609212627900_goaf088-B157","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"2025100609212627900_goaf088-B158","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1038\/s41467-022-34054-6","article-title":"Reduced alcohol preference and intake after fecal transplant in patients with alcohol use disorder is transmissible to germ-free mice","volume":"13","author":"Wolstenholme","year":"2022","journal-title":"Nat Commun"},{"key":"2025100609212627900_goaf088-B159","first-page":"bcr-2017","article-title":"Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis","volume":"2017","author":"Philips","year":"2017","journal-title":"Case Reports"},{"key":"2025100609212627900_goaf088-B160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis\u2014analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"2025100609212627900_goaf088-B161","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial","volume":"17","author":"Pande","year":"2023","journal-title":"Hepatol Int"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goaf088\/64519005\/goaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goaf088\/64519005\/goaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:21:45Z","timestamp":1759756905000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goaf088\/8275774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":161,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goaf088","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"goaf088"}}